コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 able of providing RA to DC precursors in the bone marrow microenvironment.
2 hich may contribute to independence from the bone marrow microenvironment.
3 argeting both multiple myeloma cells and the bone marrow microenvironment.
4 he expression of the chemokine CXCL12 in the bone marrow microenvironment.
5 ng migration and adhesion of WM cells in the bone marrow microenvironment.
6 leukemic cells by targeting their protective bone marrow microenvironment.
7 nitor cell movement and adherence within the bone marrow microenvironment.
8 ukemic stem cells is clonal dominance of the bone marrow microenvironment.
9 g adhesive interactions of MM cells with the bone marrow microenvironment.
10 al for survival of leukemic cells within the bone marrow microenvironment.
11 ly strong dependence on interaction with the bone marrow microenvironment.
12 actor on hematopoietic stem cells within the bone marrow microenvironment.
13 us bone formation and the homeostasis of the bone marrow microenvironment.
14 irectly or indirectly through effects on the bone marrow microenvironment.
15 ng that HNK inhibits neovascurization in the bone marrow microenvironment.
16 interactions between myeloma cells and their bone marrow microenvironment.
17 oth soluble factors and cell contacts in the bone marrow microenvironment.
18 suggest that most TSP2 is acquired from the bone marrow microenvironment.
19 y to overcome the stimulatory effects of the bone marrow microenvironment.
20 fficking and localization of MM cells in the bone marrow microenvironment.
21 W654652 acts directly on MM cells and in the bone marrow microenvironment.
22 and maturation of B-cell progenitors in the bone marrow microenvironment.
23 87 acts both directly on MM cells and in the bone marrow microenvironment.
24 stitution in the presence of an intact human bone marrow microenvironment.
25 ng at the level of B cell development in the bone marrow microenvironment.
26 eractions within the cytoarchitecture of the bone marrow microenvironment.
27 anulocytic precursors within fetal liver and bone marrow microenvironment.
28 pment of acute myeloid leukemia (AML) in the bone marrow microenvironment.
29 y for hematopoiesis to be established in the bone marrow microenvironment.
30 between interleukin-5, eosinophils, and the bone marrow microenvironment.
31 the leukemic cells in a leukemia-permissive bone marrow microenvironment.
32 pond appropriately and/or survive within the bone marrow microenvironment.
33 self-renewal and megakaryocytopoiesis in the bone marrow microenvironment.
34 , immune abnormalities, and disorders of the bone marrow microenvironment.
35 r and molecular impact of osteoblasts on the bone marrow microenvironment.
36 s well as glycolysis when located within the bone marrow microenvironment.
37 ned upon intrailiac artery delivery into the bone marrow microenvironment.
38 presentation and pathologic rewiring of the bone marrow microenvironment.
39 esponse to the hypoxic and nutrient-deprived bone marrow microenvironment.
40 s as well as adhesion molecules defining the bone marrow microenvironment.
41 yet their activation depends on a permissive bone marrow microenvironment.
42 for survival of myeloma cells outside of the bone marrow microenvironment.
43 yloidosis plasma cells and their surrounding bone marrow microenvironment.
44 nanofibril (MSCM-NF) scaffolds mimicking the bone marrow microenvironment.
45 r resistance to aging-related changes in the bone marrow microenvironment.
46 s, mutant calreticulin, and the inflammatory bone marrow microenvironment.
47 rimary MM cells alone and in the presence of bone marrow microenvironment.
48 all occur within the context of a disrupted bone marrow microenvironment.
49 utrophils and hematopoietic cells within the bone marrow microenvironment.
50 ression and represent a unique target in the bone marrow microenvironment.
51 hat underpins both the healthy and malignant bone marrow microenvironment.
52 pproach would be effective in the protective bone marrow microenvironment.
53 intained under hypoxic conditions within the bone marrow microenvironment.
54 PN development induced by the Ptpn11-mutated bone marrow microenvironment.
55 ate the expansive cell-cell crosstalk in the bone marrow microenvironment.
56 static factor secreted by osteoblasts in the bone marrow microenvironment.
57 mechanism by which ALL cells modulate their bone marrow microenvironment.
58 is with a particular emphasis on the role of bone marrow microenvironment.
59 he crosstalk between BMSCs and T(reg) in the bone marrow microenvironment.
60 ns between MM cells and stromal cells of the bone marrow microenvironment.
61 essive loss of stem cells from the postnatal bone marrow microenvironment.
62 stem cell recruiting agent, TGF-beta1 in the bone marrow microenvironment.
63 d in their respective niches by cells of the bone marrow microenvironment.
64 of myeloid cells and vascularization of the bone marrow microenvironment.
65 endent upon cellular interactions within the bone marrow microenvironment.
66 t, differentiation, and interaction with the bone marrow microenvironment.
67 esumably because of improved survival in the bone marrow microenvironment.
68 ltered ribosome function, and changes in the bone marrow microenvironment.
69 n which tumor cells receive signals from the bone marrow microenvironment.
70 al hematopoiesis in fetal liver, spleen, and bone marrow microenvironments.
71 es, and ability to mature in the specialized bone marrow microenvironments.
72 e subpopulation that is confined to specific bone marrow microenvironments.
73 c/anti-apoptotic processes but its effect on bone marrow microenvironment, a sanctuary favoring persi
74 nstrates an alternative pathway in which the bone marrow microenvironment also supports the different
75 o study consisted of cells isolated from the bone marrow microenvironment and cultured on feeder laye
76 understanding of how cancer cells hijack the bone marrow microenvironment and demonstrates that tumor
77 roliferative disorders involve targeting the bone marrow microenvironment and DNA hypermethylation.
78 Multiple myeloma (MM) cells reside in the bone marrow microenvironment and form complicated intera
80 veal a new role of NPY as a regulator of the bone marrow microenvironment and highlight the potential
81 complement each other by targeting both the bone marrow microenvironment and hypomethylating action
82 he extrinsic components are generated by the bone marrow microenvironment and include chemokine recep
83 -alpha (TNF-alpha) is present locally in the bone marrow microenvironment and induces NF-kappaB-depen
84 tezomib also decreased VEGF secretion in the bone marrow microenvironment and inhibited VEGF-triggere
87 the regulation of HSC/P retention within the bone marrow microenvironment and migration between the b
88 l roles of TIRAP, Hmgb1, and Ifngamma in the bone marrow microenvironment and provide insight into th
89 could resolve major components of the human bone marrow microenvironment and reliably characterize d
91 nd survival of multiple myeloma cells in the bone marrow microenvironment and strongly support novel
92 nxa2 regulates HSC homing and binding to the bone marrow microenvironment and suggest that Anxa2 is c
93 that maternal infections can alter both the bone marrow microenvironment and the development of B ly
94 lls exert an aberrant systemic effect on the bone marrow microenvironment and VEGF-A/VEGFR targeting
95 Thus, PMF involves complex remodeling of the bone marrow microenvironment, and glial cells represent
96 ) cells, inhibits binding of MM cells in the bone marrow microenvironment, and inhibits cytokines med
97 as sensors of age-associated changes to the bone marrow microenvironment, and observe up-regulation
98 as predominantly negative regulators of the bone-marrow microenvironment, and indicate that antagoni
99 nic cytokines and related alterations of the bone marrow microenvironment are commonly found in SM.
100 ultiple myeloma and stromal cells within the bone marrow microenvironment are essential for myeloma c
101 progenitor cell (HSPC) interactions with the bone marrow microenvironment are important for maintaini
102 st that inhibitory cytokines produced by the bone marrow microenvironment are likely to be involved i
104 vors exhibit pronounced alterations in their bone marrow microenvironment associated with impaired im
105 presumed to reside in specific niches in the bone marrow microenvironment (BMM) and may be the cause
107 een considered causative, but the age of the bone marrow microenvironment (BMM) may be contributory.
109 aematopoietic stem cells (HSC) reside in the bone marrow microenvironment (BMM), where they respond t
114 interactions between leukemia cells and the bone marrow microenvironment (BMME) that contribute sign
116 aintaining immunological homoeostasis in the bone marrow microenvironment, both in physiological cond
117 ed an anti-WM effect even in the presence of bone marrow microenvironment, both in vitro and in vivo.
118 ogenic when stimulated by FGF ligands in the bone marrow microenvironment, but is also a target for a
119 to respond to extracellular signals from the bone marrow microenvironment, but the critical intracell
120 tosis and altered adhesive properties to the bone marrow microenvironment by BCR/ABL might contribute
121 mors can achieve increased autonomy from the bone marrow microenvironment by mutations that activate
122 peutic strategy to eradicate leukemia in the bone marrow microenvironment by simultaneous targeting o
123 seous sites, increasing Wnt signaling in the bone marrow microenvironment can prevent the development
124 vidence for a multitude of ways in which the bone marrow microenvironment can promote disease pathoge
127 f acute myeloid leukemia (AML) blasts in the bone marrow microenvironment confers protection from che
129 pansion of the engrafted HSPC population and bone marrow microenvironment degradation caused by pre-t
130 not rescued by transplantation into a young bone marrow microenvironment, demonstrating cell-autonom
131 e brain, the suprachiasmatic nucleus, to the bone marrow microenvironment, directing circadian oscill
132 uclear factor kappaB ligand (RANKL) in tumor-bone marrow microenvironment drives a vicious cycle of t
136 be altered by genetical manipulation of the bone marrow microenvironment: Extramedullary bone marrow
137 l that T-ALL cells do not depend on specific bone marrow microenvironments for propagation of disease
139 granular lymphocyte (LGL) leukemia, but the bone marrow microenvironment has not been systematically
140 stem cells (HSCs) in culture outside of the bone marrow microenvironment has severely limited their
143 clude that despite the hypoxic nature of the bone marrow microenvironment, Hif-1alpha is dispensable
144 ressing AML cells directly in the SDF-1-rich bone marrow microenvironment if the survival cues of the
145 he triad of laboratory models that mimic the bone marrow microenvironment, immunodeficiency diseases
146 eoblasts but was a consequence of an altered bone marrow microenvironment imposed by Gsalpha deficien
147 previously unknown heterogeneity within the bone marrow microenvironment, imposed by the stages of b
148 (PAH) to induce B cell apoptosis within the bone marrow microenvironment in a clonally nonspecific w
149 ible to recreate all cellular aspects of the bone marrow microenvironment in an in vitro system, and
150 nd/or Bcl-xL We investigated the role of the bone marrow microenvironment in determining Bcl-2 family
151 es that BM-SEC play an important role in the bone marrow microenvironment in health and disease.
152 been accumulating to support the role of the bone marrow microenvironment in hematologic malignancies
153 nsights into the the instructive role of the bone marrow microenvironment in hematological malignanci
154 ng evidence supporting the importance of the bone marrow microenvironment in LSC survival and conside
156 These observations suggest a role for the bone marrow microenvironment in modulating the response
158 whether increasing Wnt signaling within the bone marrow microenvironment in myeloma counteracts deve
159 population of cells and on cells within the bone marrow microenvironment in normal and incisors abse
160 to determine if transplantation of an intact bone marrow microenvironment in the form of a bone graft
162 amic analysis of T-ALL interactions with the bone marrow microenvironment in vivo, supported by evide
163 py to target early survival signals from the bone marrow microenvironment, in particular FGF2, to imp
164 olecules required for the function of normal bone marrow microenvironments, in this case through the
165 is extrinsically controlled by cells of the bone marrow microenvironment, including skeletal lineage
170 exosomes in developing the AML niche of the bone marrow microenvironment, investigating their biogen
171 The interaction of stem cells with their bone marrow microenvironment is a critical process in ma
174 paB- recipients, indicating that an inflamed bone marrow microenvironment is a sufficient driver.
176 to recapitulate the conditions by which the bone marrow microenvironment is formed and establish com
178 between acute myeloid leukemia (AML) and the bone marrow microenvironment is known to control disease
179 romes, but how specific molecules impact the bone marrow microenvironment is not well elucidated.
180 It is clear that disruption of the normal bone marrow microenvironment is sufficient to promote le
183 P-BEZ235 targeted WM cells in the context of bone marrow microenvironment, leading to significant inh
187 between human prostate cancer cells and the bone marrow microenvironment mediate bone metastasis dur
188 rovide evidence that gp130 expression in the bone marrow microenvironment, most likely in endothelial
189 organization of hematopoietic cells in their bone marrow microenvironment (niche) regulates cell expa
191 ta suggest that increased IL-3 levels in the bone marrow microenvironment of MM patients with imbalan
192 ls, and mounting evidence indicates that the bone marrow microenvironment of tumour cells has a pivot
193 contributes to the favorable effects of the bone marrow microenvironment on megakaryocyte developmen
194 gnancy due, in part, to the influence of the bone marrow microenvironment on survival and drug respon
196 mplex bidirectional interactions between the bone marrow microenvironment (or niche) and hematopoieti
200 he interaction between myeloma cells and the bone marrow microenvironment, point to similar interacti
201 hat Ptpn11 activating mutations in the mouse bone marrow microenvironment promote the development and
202 n myeloma as a model to demonstrate that the bone marrow microenvironment provides a sanctuary agains
205 elucidate the stem cell niche signal in the bone marrow microenvironment, reconstitute bone marrow i
207 ause the migration of polyploid MKs from the bone marrow microenvironment requires remodeling of the
208 mation and bone resorption, and altering the bone marrow microenvironment, results in an indirect ant
209 vo drug response profiling in a model of the bone marrow microenvironment reveals powerful synergy of
210 rowth and survival signals elaborated by the bone marrow microenvironment's interaction with myeloma
211 enchymal stromal cells (MSCs) present in the bone marrow microenvironment secrete cytokines and angio
212 llowing acquisition of mitochondria from its bone marrow microenvironment.See related commentary by B
213 Overall, our data indicate that IL-21 in the bone marrow microenvironment significantly affects the b
215 ibronectin, another major constituent of the bone marrow microenvironment, stay alive and growth-arre
218 sistent with the hypothesis that a universal bone marrow microenvironment supports the expansion of m
219 exhaustion may be mediated by changes in the bone marrow microenvironment that dysregulate the wingle
220 between breast cancer cells and MSCs in the bone marrow microenvironment that facilitate adaptation
221 t result from a general defect in HSC or the bone marrow microenvironment that impairs development in
222 sociated with significant alterations in the bone marrow microenvironment that include decreased expr
223 c (in the tumor clone) and extrinsic (in the bone marrow microenvironment) that regulate tumor progre
224 n-gamma production, reprogrammed the myeloma bone marrow microenvironment through type-I/II interfero
226 inhibits MM cell growth but also acts in the bone marrow microenvironment to block angiogenesis and o
227 strates that mitochondrial transfer from the bone marrow microenvironment to HSCs is an early physiol
228 ical contribution of Ptpn11 mutations in the bone marrow microenvironment to leukaemogenesis and iden
229 l stem cells, may enhance the ability of the bone marrow microenvironment to support hematopoiesis af
230 arious therapeutic insults, residence in the bone marrow microenvironment typically confers protectio
231 Multiple myeloma is highly dependent on the bone marrow microenvironment until progressing to very a
233 ultiple myeloma cells and is abundant in the bone marrow microenvironment where it promotes tumor gro
234 alone, potentially mimicking exposure in the bone marrow microenvironment where PG concentrations are
235 hoblastic leukemia (ALL) cells reside in the bone marrow microenvironment which nurtures and protects
236 ed to excessive inflammatory activity in the bone marrow microenvironment, which could promote system
237 sults define novel epigenetic changes in the bone marrow microenvironment, which lead to beta-catenin
239 owth- and survival-supporting lymph node and bone marrow microenvironment, which results in clinicall
240 ied in the bone matrix are released into the bone marrow microenvironment, which results in recruitme
241 e our understanding of HSC metabolism in the bone marrow microenvironment, which supports the expansi
242 zomib, which target the myeloma cell and the bone-marrow microenvironment, which plays a crucial part
243 pting the protective signals provided by the bone marrow microenvironment will be critical for more e
244 yloidosis plasma cells and their surrounding bone marrow microenvironment with identification of alte
245 eraction of human preneoplastic cells in the bone marrow microenvironment with non-malignant cells.
246 nterparts in an ex vivo system mimicking the bone marrow microenvironment, would define distinctive v